Back to Articles

PCAC July 2026 Results: What the FDA Advisory Committee Decided on 7 Peptides

July 23, 20265 min readTruPeptide Editorial

What Happened

On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to evaluate seven peptide compounds for potential inclusion on the 503A bulk drug substances list. This was the first of two scheduled review groups — the second, including GHK-Cu, Melanotan II, and others, is expected by February 2027.

These seven compounds were removed from the FDA's Category 2 restricted list on April 22, 2026, but had not yet been formally evaluated for 503A inclusion. The PCAC's recommendations will inform the FDA's final decision on whether compounding pharmacies can legally prepare these compounds with a physician prescription.

Day 1 Results — July 23, 2026

BPC-157

PCAC Vote: [FAVORABLE / UNFAVORABLE / SPLIT — X to Y]

Recommendation: [INCLUDE on 503A list / DO NOT INCLUDE / DEFER for additional data]

Key discussion points:

  • [What evidence was cited by the committee]
  • [What safety concerns were raised]
  • [Any specific conditions or restrictions recommended]

What this means: [Plain-English interpretation — can patients still get this? What changes at pharmacies?]

KPV

PCAC Vote: [FAVORABLE / UNFAVORABLE / SPLIT — X to Y]

Recommendation: [INCLUDE / DO NOT INCLUDE / DEFER]

Key discussion points:

  • [Fill in from live stream]

What this means: [Interpretation]

MOTs-c

PCAC Vote: [FAVORABLE / UNFAVORABLE / SPLIT — X to Y]

Recommendation: [INCLUDE / DO NOT INCLUDE / DEFER]

Key discussion points:

  • [Fill in from live stream]

What this means: [Interpretation]

TB-500 (Thymosin Beta-4 Fragment)

PCAC Vote: [FAVORABLE / UNFAVORABLE / SPLIT — X to Y]

Recommendation: [INCLUDE / DO NOT INCLUDE / DEFER]

Key discussion points:

  • [Fill in from live stream]

What this means: [Interpretation]

Day 2 Results — July 24, 2026

Emideltide

PCAC Vote: [FAVORABLE / UNFAVORABLE / SPLIT — X to Y]

Recommendation: [INCLUDE / DO NOT INCLUDE / DEFER]

Key discussion points:

  • [Fill in from live stream]

What this means: [Interpretation]

Epitalon

PCAC Vote: [FAVORABLE / UNFAVORABLE / SPLIT — X to Y]

Recommendation: [INCLUDE / DO NOT INCLUDE / DEFER]

Key discussion points:

  • [Fill in from live stream]

What this means: [Interpretation]

Semax

PCAC Vote: [FAVORABLE / UNFAVORABLE / SPLIT — X to Y]

Recommendation: [INCLUDE / DO NOT INCLUDE / DEFER]

Key discussion points:

  • [Fill in from live stream]

What this means: [Interpretation]

Summary

| Compound | PCAC Vote | Recommendation | New Status | |----------|-----------|---------------|------------| | BPC-157 | [VOTE] | [REC] | [STATUS] | | KPV | [VOTE] | [REC] | [STATUS] | | MOTs-c | [VOTE] | [REC] | [STATUS] | | TB-500 | [VOTE] | [REC] | [STATUS] | | Emideltide | [VOTE] | [REC] | [STATUS] | | Epitalon | [VOTE] | [REC] | [STATUS] | | Semax | [VOTE] | [REC] | [STATUS] |

What Happens Next

The PCAC's vote is advisory — the FDA makes the final determination. Based on past precedent, the FDA typically follows PCAC recommendations, but the timeline for a final rule varies.

[Fill in based on actual outcomes — adjust the following sections as needed:]

For compounds that received favorable votes: The FDA will review the recommendation and issue a proposed rule to add the compound to the 503A bulk drug substances list. This process typically takes several months. Until then, the compound remains in its current regulatory gray zone.

For compounds that were deferred: The committee requested additional safety or efficacy data before making a recommendation. Sponsors or interested parties may need to submit supplementary evidence, which could delay a decision by 6-12 months.

For compounds that received unfavorable votes: An unfavorable recommendation makes 503A inclusion significantly less likely, though the FDA retains discretion. Compounds with unfavorable votes may face a longer and more uncertain path to legal compounding access.

What This Means for Patients

[Tailor to actual outcomes. Address these questions:]

  • Can my doctor still prescribe these? [Answer based on outcomes]
  • What changes at my compounding pharmacy? [Answer]
  • Should I stockpile? No. [Explain why — regulatory process takes months, current supply chains are unaffected in the short term]
  • When will the FDA make a final decision? [Timeline estimate]
  • What about Group 2 compounds? GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF are scheduled for PCAC review by February 2027. We'll cover those results the same way.

What This Means for Clinics and Pharmacies

[Practical guidance for providers — what to tell patients, what to stock, what to watch for]

This article will be updated as additional information becomes available. Last updated: [DATE AND TIME].

For educational purposes only. This is not medical or legal advice. Consult a licensed healthcare provider or attorney for guidance specific to your situation.